Sie sind nicht angemeldet! Dieses Tagebuch ist öffentlich einsehbar und wird demnächst zurückgesetzt.
 | |||||||
| |||||||
| © tratabu.de
© tratabu.de
|
Dividendenzahlungen |
|||
| Titel | Ex-Datum | Zahldatum | Bruttobetrag |
Carl Zeiss Meditec AG |
27.03.25 |
31.03.25 |
0.6000 € |
Carl Zeiss Meditec AG |
22.03.24 |
26.03.24 |
1.1000 € |
Carl Zeiss Meditec AG |
21.03.24 |
1.1000 € |
|
Carl Zeiss Meditec AG |
24.03.23 |
1.1000 € |
|
Carl Zeiss Meditec AG |
23.03.23 |
27.03.23 |
1.1000 € |
Carl Zeiss Meditec AG |
01.04.22 |
0.9000 € |
|
Carl Zeiss Meditec AG |
31.03.22 |
04.04.22 |
0.9000 € |
Carl Zeiss Meditec AG |
28.05.21 |
01.06.21 |
0.5000 € |
Carl Zeiss Meditec AG |
07.08.20 |
11.08.20 |
0.6500 € |
Carl Zeiss Meditec AG |
25.03.20 |
0.6500 € |
|
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 20.07.25 08:14:35 | Carl Zeiss Meditec (ETR:AFX) shareholders have endured a 62% loss from investing in the stock three years ago |  |
| If you love investing in stocks you're bound to buy some losers. Long term Carl Zeiss Meditec AG (ETR:AFX) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 63% in that time. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the three years that the share price fell, Carl Zeiss Meditec's earnings per share (EPS) dropped by 16% each year. This reduction in EPS is slower than the 28% annual reduction in the share price. So it seems the market was too confident about the business, in the past. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).XTRA:AFX Earnings Per Share Growth July 20th 2025 Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. A Different Perspective While the broader market gained around 23% in the last year, Carl Zeiss Meditec shareholders lost 16% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Carl Zeiss Meditec better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Carl Zeiss Meditec , and understanding them should be part of your investment process. For those who like to find winning investments this freelist of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 08.04.25 13:36:04 | Carl Zeiss Meditec AG's (ETR:AFX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? |  |
| Carl Zeiss Meditec (ETR:AFX) has had a rough month with its share price down 17%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Carl Zeiss Meditec's ROE in this article. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How To Calculate Return On Equity? Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Carl Zeiss Meditec is: 7.7% = €158m ÷ €2.1b (Based on the trailing twelve months to December 2024). The 'return' is the yearly profit. One way to conceptualize this is that for each €1 of shareholders' capital it has, the company made €0.08 in profit. Check out our latest analysis for Carl Zeiss Meditec What Has ROE Got To Do With Earnings Growth? Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. Carl Zeiss Meditec's Earnings Growth And 7.7% ROE When you first look at it, Carl Zeiss Meditec's ROE doesn't look that attractive. Yet, a closer study shows that the company's ROE is similar to the industry average of 9.5%. Having said that, Carl Zeiss Meditec has shown a modest net income growth of 8.9% over the past five years. Considering the moderately low ROE, it is quite possible that there might be some other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio. Next, on comparing with the industry net income growth, we found that the growth figure reported by Carl Zeiss Meditec compares quite favourably to the industry average, which shows a decline of 2.3% over the last few years. Story Continues XTRA:AFX Past Earnings Growth April 8th 2025 The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is AFX fairly valued? This infographic on the company's intrinsic value has everything you need to know. Is Carl Zeiss Meditec Efficiently Re-investing Its Profits? With a three-year median payout ratio of 34% (implying that the company retains 66% of its profits), it seems that Carl Zeiss Meditec is reinvesting efficiently in a way that it sees respectable amount growth in its earnings and pays a dividend that's well covered. Additionally, Carl Zeiss Meditec has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 31%. Still, forecasts suggest that Carl Zeiss Meditec's future ROE will rise to 11% even though the the company's payout ratio is not expected to change by much. Conclusion Overall, we feel that Carl Zeiss Meditec certainly does have some positive factors to consider. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 23.03.25 07:50:56 | Carl Zeiss Meditec AG (ETR:AFX) Stock Goes Ex-Dividend In Just Three Days | |
| Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Carl Zeiss Meditec AG (ETR:AFX) is about to go ex-dividend in just 3 days. The ex-dividend date is two business days before a company's record date in most cases, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is important as the process of settlement involves at least two full business days. So if you miss that date, you would not show up on the company's books on the record date. In other words, investors can purchase Carl Zeiss Meditec's shares before the 27th of March in order to be eligible for the dividend, which will be paid on the 31st of March. The company's next dividend payment will be €0.60 per share, and in the last 12 months, the company paid a total of €0.60 per share. Looking at the last 12 months of distributions, Carl Zeiss Meditec has a trailing yield of approximately 0.9% on its current stock price of €63.95. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. So we need to investigate whether Carl Zeiss Meditec can afford its dividend, and if the dividend could grow. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Carl Zeiss Meditec paid out a comfortable 34% of its profit last year. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. The company paid out 103% of its free cash flow over the last year, which we think is outside the ideal range for most businesses. Cash flows are usually much more volatile than earnings, so this could be a temporary effect - but we'd generally want to look more closely here. Carl Zeiss Meditec paid out less in dividends than it reported in profits, but unfortunately it didn't generate enough cash to cover the dividend. Cash is king, as they say, and were Carl Zeiss Meditec to repeatedly pay dividends that aren't well covered by cashflow, we would consider this a warning sign. Check out our latest analysis for Carl Zeiss Meditec Click here to see the company's payout ratio, plus analyst estimates of its future dividends.XTRA:AFX Historic Dividend March 23rd 2025 Have Earnings And Dividends Been Growing? Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. That explains why we're not overly excited about Carl Zeiss Meditec's flat earnings over the past five years. We'd take that over an earnings decline any day, but in the long run, the best dividend stocks all grow their earnings per share. Earnings have been growing somewhat, but we're concerned dividend payments consumed most of the company's cash flow over the past year. Story Continues Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Carl Zeiss Meditec has delivered 4.1% dividend growth per year on average over the past 10 years. The Bottom Line Is Carl Zeiss Meditec an attractive dividend stock, or better left on the shelf? Earnings per share have barely grown in this time, and although Carl Zeiss Meditec is paying out a low percentage of its profit, its dividend was not well covered by free cash flow. It's not common to see a company paying out a limited amount of its profits yet a substantially higher percentage of its cash flow, so we'd flag this as a concern. While it does have some good things going for it, we're a bit ambivalent and it would take more to convince us of Carl Zeiss Meditec's dividend merits. If you want to look further into Carl Zeiss Meditec, it's worth knowing the risks this business faces. Every company has risks, and we've spotted 2 warning signs for Carl Zeiss Meditec you should know about. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 22.03.25 07:47:51 | Carl Zeiss Meditec's (ETR:AFX) Dividend Will Be Reduced To €0.60 | |
| Carl Zeiss Meditec AG (ETR:AFX) has announced that on 31st of March, it will be paying a dividend of€0.60, which a reduction from last year's comparable dividend. This means that the annual payment is 0.9% of the current stock price, which is lower than what the rest of the industry is paying. While the dividend yield is important for income investors, it is also important to consider any large share price moves, as this will generally outweigh any gains from distributions. Investors will be pleased to see that Carl Zeiss Meditec's stock price has increased by 40% in the last 3 months, which is good for shareholders and can also explain a decrease in the dividend yield. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Carl Zeiss Meditec's Future Dividend Projections Appear Well Covered By Earnings It would be nice for the yield to be higher, but we should also check if higher levels of dividend payment would be sustainable. Before making this announcement, Carl Zeiss Meditec was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business. Over the next year, EPS is forecast to expand by 81.3%. If the dividend continues along recent trends, we estimate the payout ratio will be 20%, which is in the range that makes us comfortable with the sustainability of the dividend.XTRA:AFX Historic Dividend March 22nd 2025 View our latest analysis for Carl Zeiss Meditec Dividend Volatility The company's dividend history has been marked by instability, with at least one cut in the last 10 years. The dividend has gone from an annual total of €0.40 in 2015 to the most recent total annual payment of €0.60. This implies that the company grew its distributions at a yearly rate of about 4.1% over that duration. Modest growth in the dividend is good to see, but we think this is offset by historical cuts to the payments. It is hard to live on a dividend income if the company's earnings are not consistent. The Dividend's Growth Prospects Are Limited With a relatively unstable dividend, it's even more important to evaluate if earnings per share is growing, which could point to a growing dividend in the future. Carl Zeiss Meditec hasn't seen much change in its earnings per share over the last five years. Our Thoughts On Carl Zeiss Meditec's Dividend In summary, dividends being cut isn't ideal, however it can bring the payment into a more sustainable range. The payments haven't been particularly stable and we don't see huge growth potential, but with the dividend well covered by cash flows it could prove to be reliable over the short term. This company is not in the top tier of income providing stocks. Story Continues It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've picked out 2 warning signs for Carl Zeiss Meditec that investors should know about before committing capital to this stock. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 21.03.25 14:00:00 | ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care | |
| TORONTO, March 21, 2025 /CNW/ -- ZEISS Medical Technology announced today the availability in Canada of the ZEISS VISULAS Combi, an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution. Designed for the treatment of retina, cataract, and glaucoma conditions, the ZEISS VISULAS Combi streamlines workflows with customizable modules, a uniform interface, and space-saving features. It enables seamless eye care without the need for time-consuming changes or relocation of the patient, enhancing both clinical efficiency and the patient experience.ZEISS VISULAS combi Dr. Hady Saheb, a renowned glaucoma expert and President of the Canadian Glaucoma Society, shares, "As an ophthalmologist committed to delivering the best possible care for my patients, I am excited to see the ZEISS VISULAS Combi in practice. I had the opportunity to use the SLT component in conjunction with the ZEISS FORUM and Imaging Solution, and the experience was seamless. The ability to generate treatment reports automatically—without the need to manually enter every detail—is a time-saver for those using the ZEISS FORUM and Imaging Solution. Additionally, the HD Imaging Solution has been invaluable for educating the various learners on the team, eliminating the need for a co-observation tube and allowing multiple learners to watch simultaneously. The SLT laser is performed without bubbles, and the clinical results have also been very promising so far. The ZEISS VISULAS Combi promises to be an exciting new tool for our patients, as the role of SLT laser continues to expand in glaucoma patient care" With Health Canada's approval, ZEISS is pleased to introduce this cutting-edge technology to the Canadian ophthalmology market. Abrar Esop, Head of Medical Technology at ZEISS Canada, explains, "At ZEISS, we are committed to advancing ophthalmic care by improving clinical efficiency and supporting innovation and education. The ZEISS VISULAS Combi embodies our dedication to empowering clinicians and shaping the future of ophthalmology. With its multi-disciplinary capabilities, the ZEISS VISULAS Combi allows ophthalmologists to see more, do more, and treat more—all with one device. Previously, this would have required multiple systems, additional training, and larger workspaces. This platform represents a future-proof investment for ophthalmologists that provides precision and adaptability in one streamlined system." The ZEISS VISULAS Combi sets a new standard in ophthalmic care, offering a versatile and innovative solution that helps simplify the complexities of modern eye care while enabling exceptional outcomes for both patients and practitioners. Discover more: ZEISS VISULAS Combi Story Continues For ophthalmologists based in Canada who would like more information about the ZEISS VISULAS Combi, please contact czcmed@zeiss.com. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. www.zeiss.com/newsroom Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: www.zeiss.com/medZEISS (PRNewsfoto/Carl Zeiss Meditec) SOURCE Carl Zeiss Meditec AGCision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2025/21/c2032.html View Comments |
||
| 17.03.25 05:07:46 | European Market's Hidden Gems: ASML Holding And 2 Other Value Stocks | |
| In the midst of economic uncertainties and fluctuating indices, the European market has been navigating challenges such as U.S. trade tariffs and monetary policy shifts, with major stock indexes showing mixed performances. Despite these hurdles, opportunities arise for discerning investors to identify undervalued stocks that may offer potential value in a volatile environment. Top 10 Undervalued Stocks Based On Cash Flows In Europe Name Current Price Fair Value (Est) Discount (Est) Telefonaktiebolaget LM Ericsson (OM:ERIC B) SEK83.36 SEK164.66 49.4% Fondia Oyj (HLSE:FONDIA) €5.45 €10.63 48.7% JOST Werke (XTRA:JST) €50.00 €98.51 49.2% Storytel (OM:STORY B) SEK92.70 SEK180.62 48.7% dormakaba Holding (SWX:DOKA) CHF680.00 CHF1358.27 49.9% Star7 (BIT:STAR7) €6.20 €12.36 49.8% Cint Group (OM:CINT) SEK6.40 SEK12.79 49.9% Neosperience (BIT:NSP) €0.53 €1.06 49.9% Cavotec (OM:CCC) SEK17.35 SEK34.07 49.1% Fodelia Oyj (HLSE:FODELIA) €7.12 €13.91 48.8% Click here to see the full list of 199 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's uncover some gems from our specialized screener. ASML Holding Overview: ASML Holding N.V. specializes in providing lithography solutions essential for semiconductor equipment systems, with a market capitalization of approximately €257.88 billion. Operations: The company's revenue is primarily generated from its Semiconductor Equipment and Services segment, which accounted for €28.26 billion. Estimated Discount To Fair Value: 15.7% ASML Holding's recent strategic partnership with imec underscores its commitment to innovation and sustainability in the semiconductor industry. The stock trades at approximately €655.7, below its estimated fair value of €778.05, suggesting potential undervaluation based on cash flows. Despite insider selling, ASML is expected to achieve annual earnings growth of 15.4%, surpassing the Dutch market average, while maintaining a high return on equity forecasted at 45.9% over three years. The analysis detailed in our ASML Holding growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of ASML Holding.ENXTAM:ASML Discounted Cash Flow as at Mar 2025 Airbus Overview: Airbus SE, along with its subsidiaries, is involved in the design, manufacture, and delivery of aeronautics and aerospace products, services, and solutions globally with a market cap of approximately €133.32 billion. Operations: The company's revenue is primarily generated through its segments: Airbus Helicopters (€7.94 billion), Airbus Defence and Space (€12.08 billion), and Airbus, which includes Holding Function and Bank Activities (€50.65 billion). Story Continues Estimated Discount To Fair Value: 47.1% Airbus is trading at €169.2, significantly below its estimated fair value of €319.77, highlighting potential undervaluation based on cash flows. Earnings have grown 42.2% annually over the past five years and are forecast to grow 17.3% per year, outpacing the French market's average growth rate. Recent regulatory approval in China for value-added telecom services could enhance revenue streams, while ongoing negotiations with Spirit AeroSystems may impact future operations and asset allocations in Belfast. According our earnings growth report, there's an indication that Airbus might be ready to expand. Click to explore a detailed breakdown of our findings in Airbus' balance sheet health report.ENXTPA:AIR Discounted Cash Flow as at Mar 2025 Carl Zeiss Meditec Overview: Carl Zeiss Meditec AG is a medical technology company operating in Germany, the rest of Europe, North America, and Asia with a market cap of approximately €5.61 billion. Operations: The company's revenue is primarily derived from two segments: Ophthalmic Devices, including Surgical Ophthalmology, which contributes approximately €1.61 billion, and Microsurgery, which accounts for about €467.36 million. Estimated Discount To Fair Value: 30.5% Carl Zeiss Meditec is trading at €64.1, significantly below its estimated fair value of €92.21, suggesting undervaluation based on cash flows. Despite a decline in net income to €15.7 million from €37.4 million year-over-year, earnings are expected to grow over 20% annually, surpassing the German market's growth rate of 16.5%. Recent FDA approval for the MEL 90 excimer laser could bolster revenue through expanded offerings in U.S. refractive clinics. Our comprehensive growth report raises the possibility that Carl Zeiss Meditec is poised for substantial financial growth. Dive into the specifics of Carl Zeiss Meditec here with our thorough financial health report.XTRA:AFX Discounted Cash Flow as at Mar 2025 Where To Now? Click through to start exploring the rest of the 196 Undervalued European Stocks Based On Cash Flows now. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTAM:ASML ENXTPA:AIR and XTRA:AFX. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments |
||
| 10.03.25 11:07:08 | When Should You Buy Carl Zeiss Meditec AG (ETR:AFX)? | |
| Carl Zeiss Meditec AG (ETR:AFX), is not the largest company out there, but it saw a significant share price rise of 35% in the past couple of months on the XTRA. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Let’s take a look at Carl Zeiss Meditec’s outlook and value based on the most recent financial data to see if the opportunity still exists. View our latest analysis for Carl Zeiss Meditec What Is Carl Zeiss Meditec Worth? The stock seems fairly valued at the moment according to our valuation model. It’s trading around 11% below our intrinsic value, which means if you buy Carl Zeiss Meditec today, you’d be paying a reasonable price for it. And if you believe that the stock is really worth €68.46, then there’s not much of an upside to gain from mispricing. So, is there another chance to buy low in the future? Given that Carl Zeiss Meditec’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility. What kind of growth will Carl Zeiss Meditec generate?XTRA:AFX Earnings and Revenue Growth March 10th 2025 Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. Carl Zeiss Meditec's earnings over the next few years are expected to increase by 77%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What This Means For You Are you a shareholder? AFX’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you’ve been keeping an eye on AFX, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Story Continues So while earnings quality is important, it's equally important to consider the risks facing Carl Zeiss Meditec at this point in time. You'd be interested to know, that we found 3 warning signs for Carl Zeiss Meditec and you'll want to know about them. If you are no longer interested in Carl Zeiss Meditec, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 16.02.25 07:27:13 | Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Smaller Dividend Than Last Year | |
| Carl Zeiss Meditec AG's (ETR:AFX) dividend is being reduced from last year's payment covering the same period to €0.60 on the 31st of March. This means that the annual payment is 1.1% of the current stock price, which is lower than what the rest of the industry is paying. See our latest analysis for Carl Zeiss Meditec Carl Zeiss Meditec's Future Dividend Projections Appear Well Covered By Earnings If it is predictable over a long period, even low dividend yields can be attractive. Before making this announcement, Carl Zeiss Meditec was easily earning enough to cover the dividend. This means that most of what the business earns is being used to help it grow. Looking forward, earnings per share is forecast to rise by 79.5% over the next year. If the dividend continues on this path, the payout ratio could be 20% by next year, which we think can be pretty sustainable going forward.XTRA:AFX Historic Dividend February 16th 2025 Dividend Volatility The company's dividend history has been marked by instability, with at least one cut in the last 10 years. Since 2015, the annual payment back then was €0.40, compared to the most recent full-year payment of €0.60. This implies that the company grew its distributions at a yearly rate of about 4.1% over that duration. We're glad to see the dividend has risen, but with a limited rate of growth and fluctuations in the payments the total shareholder return may be limited. The Dividend's Growth Prospects Are Limited With a relatively unstable dividend, it's even more important to see if earnings per share is growing. However, Carl Zeiss Meditec's EPS was effectively flat over the past five years, which could stop the company from paying more every year. In Summary Overall, it's not great to see that the dividend has been cut, but this might be explained by the payments being a bit high previously. The payments haven't been particularly stable and we don't see huge growth potential, but with the dividend well covered by cash flows it could prove to be reliable over the short term. We would be a touch cautious of relying on this stock primarily for the dividend income. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've picked out 3 warning signs for Carl Zeiss Meditec that investors should know about before committing capital to this stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 13.02.25 17:00:31 | Carl Zeiss Meditec AG (CZMWF) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Market ... | |
| Release Date: February 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Carl Zeiss Meditec AG (CZMWF) reported a 3.2% increase in revenue for Q1 2025 compared to the same period last year. The company saw a significant recovery in order entry, reaching 522 million, a 34.4% increase at constant currency. The approval of the Visa Max 800 in China was achieved earlier than expected, potentially boosting future sales. Recurring revenue now accounts for 47.3% of total revenue, indicating a stable income stream. The company has implemented strict cost control measures, leading to a reduction in R&D expenses and underlying operating expenses. Negative Points When adjusted for FX and acquisitions, revenue actually declined by 7.3% due to strong prior year comparisons and a weaker investment climate, particularly in China. EBITA declined by 23.5% compared to the prior year, resulting in a margin drop from 9.7% to 7.2%. The gross margin decreased to 51.4% due to an unfavorable product mix and price cuts in IOLs. Net income dropped significantly from 37 million to 160 million, with earnings per share declining by 57.1%. The company faces ongoing challenges in China, with a decline in sales due to product cycle transitions and restrictive investment climates. Q & A Highlights Warning! GuruFocus has detected 4 Warning Signs with CZMWF. Q: Can you provide an update on the Chinese New Year season, particularly regarding volume trends and pricing pressures? Also, how is the demand for the VisuMax 800 following its earlier-than-expected approval in China? A: We observed stabilization in the Chinese market, especially in refractive laser surgery, despite the dynamic environment. The VisuMax 800 has been well-received, with customers excited about its new features. We are maintaining a high pace of innovation to support market share growth, particularly with Smile Pro and other advanced procedures. (Respondent: CEO) Q: Why hasn't the guidance been clarified with more granularity as previously implied? Has visibility improved at all? A: We are confirming the guidance given earlier, and uncertainties remain high. We haven't gained much more visibility, especially regarding the spring peak in China for our refractive business. Major influences like tariff escalations are still uncertain. (Respondent: CFO) Q: Can you quantify what you mean by "moderate growth" and provide more clarity on the top-line guidance? A: We aim to grow at least as fast as the market, targeting low single-digit growth. The growth depends heavily on market composition and conditions, particularly in China, where we see stabilization and opportunities due to new innovations. (Respondent: CEO) Story Continues Q: How has the volume of IOLs developed, and what are your expectations for market share and volume growth? A: We have seen a strong increase in units and volume, indicating a market share increase. Our strategy focuses on premium lenses and higher price realization in private sector clinics, which is working well. We expect volume growth to contribute positively to gross profit. (Respondent: CFO) Q: Regarding the VisuMax 800, how do you expect it to stimulate demand given the current underutilization of the installed base? A: The VisuMax 800, with its advanced features and new applications like presbyopia treatment, is expected to create significant value for customers. We anticipate strong demand for replacements and new installations, particularly in China, where the market is poised for growth. (Respondent: CEO) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments |
||
| 10.02.25 06:18:54 | The past three years for Carl Zeiss Meditec (ETR:AFX) investors has not been profitable | |
| Carl Zeiss Meditec AG (ETR:AFX) shareholders should be happy to see the share price up 21% in the last month. But that is small recompense for the exasperating returns over three years. Regrettably, the share price slid 57% in that period. Some might say the recent bounce is to be expected after such a bad drop. After all, could be that the fall was overdone. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Check out our latest analysis for Carl Zeiss Meditec To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). Carl Zeiss Meditec saw its EPS decline at a compound rate of 8.2% per year, over the last three years. This reduction in EPS is slower than the 24% annual reduction in the share price. So it seems the market was too confident about the business, in the past. You can see below how EPS has changed over time (discover the exact values by clicking on the image).XTRA:AFX Earnings Per Share Growth February 10th 2025 It's probably worth noting that the CEO is paid less than the median at similar sized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.. A Different Perspective Investors in Carl Zeiss Meditec had a tough year, with a total loss of 48% (including dividends), against a market gain of about 18%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 8% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Carl Zeiss Meditec that you should be aware of. Story Continues Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this freelist of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
